Page last updated: 2024-11-05

tranexamic acid and Placenta Increta

tranexamic acid has been researched along with Placenta Increta in 6 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Placenta Increta: Invasion of CHORIONIC VILLI occurs deep into the MYOMETRIUM.

Research Excerpts

ExcerptRelevanceReference
"This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)."8.31Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023)
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid."5.42Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015)
"This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)."4.31Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023)
" A rapid recourse to prostaglandins (sulprostone in France) may reverse uterine atony."3.83Major obstetric hemorrhage. ( Le Gouez, A; Mercier, FJ, 2016)
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid."1.42Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Munoz, JL1
Blankenship, LM1
Ramsey, PS1
McCann, GA1
Neely, D1
Elnour, S1
Schröder, L1
Pötzsch, B1
Rühl, H1
Gembruch, U1
Merz, WM1
Mauritz, AA1
Dominguez, JE1
Guinn, NR1
Gilner, J1
Habib, AS1
Le Gouez, A1
Mercier, FJ1
As, AK1
Hagen, P1
Webb, JB1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]Phase 311,000 participants (Actual)Interventional2018-03-15Completed
Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section[NCT02350179]Phase 1/Phase 2100 participants (Anticipated)Interventional2014-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hemoglobin

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Interventiongrams per deciliter (Mean)
Tranexamic Acid-1.8
Placebo-1.9

Length of Stay

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Interventiondays (Median)
Tranexamic Acid3
Placebo3

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

(NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid35
Placebo32

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid108
Placebo109

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid233
Placebo231

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid892
Placebo986

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid20
Placebo19

Number of Participants Who Were Transfused With Other Blood Products

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid29
Placebo31

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid649
Placebo732

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid12
Placebo13

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

InterventionParticipants (Count of Participants)
Tranexamic Acid339
Placebo368

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

InterventionParticipants (Count of Participants)
Tranexamic Acid201
Placebo233

Number of Participants With Postpartum Infectious Complications

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid162
Placebo125

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid2
Placebo0

Other Studies

6 other studies available for tranexamic acid and Placenta Increta

ArticleYear
Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum.
    American journal of obstetrics and gynecology, 2023, Volume: 229, Issue:1

    Topics: Blood Transfusion; Cesarean Section; Hysterectomy; Placenta Accreta; Postpartum Hemorrhage; Pregnanc

2023
Anaesthesia for abnormally invasive placenta: cell salvage and tranexamic acid.
    International journal of obstetric anesthesia, 2017, Volume: 32

    Topics: Anesthesia; Anesthesiology; Antifibrinolytic Agents; Female; Humans; Placenta; Placenta Accreta; Pre

2017
Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta.
    Obstetrics and gynecology, 2015, Volume: 126, Issue:5

    Topics: Adult; Antifibrinolytic Agents; Female; Fibrinolysis; Hemorrhage; Humans; Placenta Accreta; Pregnanc

2015
Blood-Conservation Strategies in a Blood-Refusal Parturient with Placenta Previa and Placenta Percreta.
    A & A case reports, 2016, Mar-01, Volume: 6, Issue:5

    Topics: Adult; Bloodless Medical and Surgical Procedures; Combined Modality Therapy; Erythropoietin; Female;

2016
Major obstetric hemorrhage.
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2016, Volume: 23, Issue:4

    Topics: Blood Component Transfusion; Combined Modality Therapy; Dinoprostone; Factor VIIa; Female; Fibrinoge

2016
Tranexamic acid in the management of postpartum haemorrhage.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12

    Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post

1996
Tranexamic acid in the management of postpartum haemorrhage.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12

    Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post

1996
Tranexamic acid in the management of postpartum haemorrhage.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12

    Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post

1996
Tranexamic acid in the management of postpartum haemorrhage.
    British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:12

    Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post

1996